Magazine Article | February 1, 2019

Why 2018 Was The Year Of Real-World Evidence For Biosimilars

Source: Life Science Leader

By Anna Rose Welch, Editor, Biosimilar Development

In 2018, it became clear to me that the biosimilar industry had taken the need for real-world evidence (RWE) to heart. At a conference in Brazil in August, I was asked to present on the RWE efforts I felt were particularly notable. In doing the research for this presentation, my eyes were opened to the pace at which biosimilar evidence is being released.